Company expects cost savings in future periods from April 2026 reduction in force
Company says tariffs may continue to materially impact costs in future periods
Company notes ongoing uncertainty regarding timing of future international orders
Overview
US medical device maker's Q2 sales fell yr/yr due to timing of EasyPoint needle orders
Operating loss for Q2 remained unchanged from prior year
Net income for Q2 was positive due to $6.4 mln gain on sale of equity securities
Key details
Metric
Actual
Q2 Sales
$7.2 mln
Q2 Operating Income
-$5.1 mln
Result drivers
EasyPoint needle sales - Co said lower Q2 sales were primarily due to timing of EasyPoint needle orders, with prior-year period boosted by atypical flu season purchasing patterns
International sales drop - International revenues and EasyPoint needle sales declined, with ongoing uncertainty about timing of future international orders
RVP•
